The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

A doctor and a patient discussing a therapy plan that includes pharmaceutical products. GSK plc (NYSE:GSK) develops and ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

Full Year 2024 Results Key Financial Results Revenue: UK£31.4b (up 3.5% from FY 2023). Net ...

The growth of these products comes from strong patient demand. These two long-acting medicines contributed more than 50% of the total HIV growth and now account for 20% of HIV sales. In 2025, GSK ...

This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

GSK's revenue and EPS exceeded my expectations ... part of the dolutegravir products in the chart below. Let's dive into the reasons for Dovato's sales growth, which totaled $813 million, up ...

LOS ANGELES, March 11, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against GSK plc.

The deal, signed in 2016, granted GSK a worldwide, royalty-bearing antibody sequence pair-specific exclusive license to research, develop and commercialize licensed products. Later, in 2019 ...